The findings of a phase III trial in patients with advanced-stage ALK-rearranged non-small-cell lung cancer (NSCLC) reveal the superior efficacy of the ALK inhibitor ceritinib compared with that of platinum-based chemotherapy, in the first-line setting. Patients received four cycles of either ceritinib or cisplatin/carboplatin plus pemetrexed, resulting in a significant improvement in the median progression-free survival duration in patients receiving ceritinib (16.6 months versus 8.1 months). However, these improvements come at a price: diarrhoea, nausea and vomiting were all more common adverse events in patients receiving ceritinib compared with those receiving carboplatin or cisplatin. These data indicate that ceritinib provides a more effective but more toxic alternative to platinum-based chemotherapy for patients with ALK-rearranged NSCLC.
References
Soria, J. C. et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet http://dx.doi.org/10.1016/S0140-6736(17)30123-X (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Ceritinib is superior to frontline chemotherapy. Nat Rev Clin Oncol 14, 198 (2017). https://doi.org/10.1038/nrclinonc.2017.20
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.20